Safety and tolerability of antipsychotic polypharmacy

Bibliography

• Stahl SM. Antipsychotic polypharmacy: squandering precious resources? J Clin Psychiatry 2002;63:93-4
   PubMed Web of Science ®Google Scholar
• Baandrup L, Sorensen J, Lublin H, Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis. Eur J Health Econ 2011 Mar 31. [Epub ahead of print] PubMed PMID:21452062
   PubMed Web of Science ®Google Scholar
• Zink M, Englisch S, Meyer-Lindenberg A. Polypharmacy in schizophrenia. Curr Opin Psychiatry 2010;23:103-11
   PubMed Web of Science ®Google Scholar
• Nielsen J, le Quach P, Emborg C, 10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr Scand 2010;122:356-66
   PubMed Web of Science ®Google Scholar
• Goodwin G, Fleischhacker W, Arango C, Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol 2009;19:520-32
   PubMed Web of Science ®Google Scholar
• Correll CU, Rummel-Kluge C, Corves C, Antipsychotic combinations vs monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 2009;35:443-57
   PubMed Web of Science ®Google Scholar
• Barbui C, Signoretti A, Mule S, Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull 2009;35:458-68
   PubMed Web of Science ®Google Scholar
• Joukamaa M, Heliovaara M, Knekt P, Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 2006;188:122-7
   PubMed Web of Science ®Google Scholar
• Gallego JA, Bonetti J, Zhang J, Prevalence and correlates of antipsychotic polypharmacy: a systematic review and metaregression of global and regional trends from the 1970s to 2009. Schizophr Res; In press
   Web of Science ®Google Scholar
• Correll CU, Shaikh L, Gallego JA, Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophr Res 2011; [Epub ahead of print] PubMed PMID:21419603
   Web of Science ®Google Scholar
• Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 2010;25(Suppl 2):S12-21
   PubMed Web of Science ®Google Scholar
• Iqbal N, Lambert T, Masand P. Akathisia: problem of history or concern of today. CNS Spectr 2007;12:1-13
   PubMed Web of Science ®Google Scholar
• Rupniak NM, Jenner P, Marsden CD. Acute dystonia induced by neuroleptic drugs. Psychopharmacology (Berl) 1986;88:403-19
   PubMed Web of Science ®Google Scholar
• Hong IS, Bishop JR. Anticholinergic use in children and adolescents after initiation of antipsychotic therapy. Ann Pharmacother 2010;44:1171-80
   PubMed Web of Science ®Google Scholar
• Procyshyn RM, Honer WG, Wu TK, Persistent antipsychotic polypharmacy and excessive dosing in the community psychiatric treatment setting: a review of medication profiles in 435 Canadian outpatients. J Clin Psychiatry 2010;71:566-73
   PubMed Web of Science ®Google Scholar
• Xiang YT, Weng YZ, Leung CM, Clinical and social determinants of antipsychotic polypharmacy for Chinese patients with schizophrenia. Pharmacopsychiatry 2007;40:47-52
   PubMed Web of Science ®Google Scholar
• Kreyenbuhl JA, Valenstein M, McCarthy JF, Long-term antipsychotic polypharmacy in the VA health system: patient characteristics and treatment patterns. Psychiatr Serv 2007;58:489-95
   PubMed Web of Science ®Google Scholar
• Megna JL, Kunwar AR, Mahlotra K, A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness. J Psychiatr Pract 2007;13:129-37
   PubMedGoogle Scholar
• Chakos MH, Glick ID, Miller AL, Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 2006;57:1094-101
   PubMed Web of Science ®Google Scholar
• Carnahan RM, Lund BC, Perry PJ, Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy. Acta Psychiatr Scand 2006;113:135-41
   PubMed Web of Science ®Google Scholar
• Ganguly R, Kotzan JA, Miller LS, Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004;65:1377-88
   PubMed Web of Science ®Google Scholar
• Procyshyn RM, Kennedy NB, Tse G, Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001;46:334-9
   PubMed Web of Science ®Google Scholar
• Taylor D, Mace S, Mir S, A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. Int J Psychiatry Clin Pract 2000;4:41-6
   PubMed Web of Science ®Google Scholar
• Florez Menendez G, Blanco Ramos M, Gomez-Reino Rodriguez I, Polipharmacy in the antipsychotic prescribing in practices psychiatric out-patient clinic. Actas Esp Psiquiatr 2004;32:333-9
   PubMed Web of Science ®Google Scholar
• Mason AS, Nerviano V, DeBurger RA. Patterns of antipsychotic drug use in four Southeastern state hospitals. Dis Nerv Syst 1977;38:541-5
   PubMedGoogle Scholar
• Clark A, Holden N. The persistence of prescribing habits: a survey and follow-up of prescribing to chronic hospital in-patients. Br J Psychiatry 1987;150:88
   PubMed Web of Science ®Google Scholar
• Sim K, Su A, Fujii S, Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 2004;58:178-83
   PubMed Web of Science ®Google Scholar
• Kiivet RA, Llerena A, Dahl ML, Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. Br J Clin Pharmacol 1995;40:467-76
   PubMed Web of Science ®Google Scholar
• Tognoni G. Pharmacoepidemiology of psychotropic drugs in patients with severe mental disorders in Italy. Eur J Clin Pharmacol 1999;55:685-90
   PubMed Web of Science ®Google Scholar
• De Hert M, Wampers M, Peuskens J. Pharmacological treatment of hospitalised schizophrenic patients in Belgium. Int J Psychiatry Clin Pract 2006;10:285-90
   PubMed Web of Science ®Google Scholar
• De Hert M, Wampers M, van Winkel R, Anticholinergic use in hospitalised schizophrenic patients in Belgium. Psychiatry Res 2007;152:165-72
   PubMed Web of Science ®Google Scholar
• Hanssens L, De Hert M, Wampers M, Pharmacological treatment of ambulatory schizophrenic patients in Belgium. Clin Pract Epidemol Ment Health 2006;2:11
   PubMedGoogle Scholar
• Lin CH, Kuo CC, Chou LS, A randomized, double-blind comparison of risperidone versus low-dose risperidone plus low-dose haloperidol in treating schizophrenia. J Clin Psychopharmacol 2010;30:518-25
   PubMed Web of Science ®Google Scholar
• Kane JM, Correll CU, Goff DC, A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J Clin Psychiatry 2009;70:1348-57
   PubMed Web of Science ®Google Scholar
• Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. J Clin Psychiatry 1996;57:395-7
   PubMed Web of Science ®Google Scholar
• Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry 2000;61(Suppl 4):5-9
   PubMedGoogle Scholar
• Tsai G, Goff DC, Chang RW, Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998;155:1207-13
   PubMed Web of Science ®Google Scholar
• Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007;164:870-6
   PubMed Web of Science ®Google Scholar
• Wieck A, Haddad PM. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003;182:199-204
   PubMed Web of Science ®Google Scholar
• Petty RG. Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 1999;35(Suppl):S67-73
   PubMed Web of Science ®Google Scholar
• Montgomery J, Winterbottom E, Jessani M, Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry 2004;65:1491-8
   PubMed Web of Science ®Google Scholar
• Henderson DC, Goff DC, Connolly CE, Risperidone added to clozapine: impact on serum prolactin levels. J Clin Psychiatry 2001;62:605-8
   PubMed Web of Science ®Google Scholar
• Anil YAE, Kivircik ABB, Turgut TI, A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005;66:63
   PubMed Web of Science ®Google Scholar
• Shiloh R, Zemishlany Z, Aizenberg D, Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997;171:569-73
   PubMed Web of Science ®Google Scholar
• Zink M, Kuwilsky A, Krumm B, Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial. J Psychopharmacol 2009;23:305-14
   PubMed Web of Science ®Google Scholar
• Kuwilsky A, Krumm B, Englisch S, Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. Pharmacopsychiatry 2010;43:216-20. PubMed PMID:20589598
   PubMed Web of Science ®Google Scholar
• Shores LE. Normalization of risperidone-induced hyperprolactinemia with the addition of aripiprazole. Psychiatry (Edgmont) 2005;2:42-5
   PubMedGoogle Scholar
• Mir A, Shivakumar K, Williamson RJ, Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol 2008;22:244-53
   PubMed Web of Science ®Google Scholar
• Chen CK, Huang YS, Ree SC, Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1495-9
   PubMed Web of Science ®Google Scholar
• Yasui-Furukori N, Furukori H, Sugawara N, Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol 2010;30:596-9
   PubMed Web of Science ®Google Scholar
• Shim JC, Shin JG, Kelly DL, Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007;164:1404-10
   PubMed Web of Science ®Google Scholar
• Malik P. Sexual dysfunction in schizophrenia. Curr Opin Psychiatry 2007;20:138-42
   PubMed Web of Science ®Google Scholar
• Brooks JO III, Goldberg JF, Ketter TA, Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the systematic treatment enhancement program for bipolar disorder. J Clin Psychiatry 2011;72:240-7
   PubMed Web of Science ®Google Scholar
• De Hert M, Detraux J, van Winkel R, Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol2011; Oct 18;8(2):114-26; doi: 10.1038/nrendo.2011.156. PubMed PMID: 22009159
   PubMed Web of Science ®Google Scholar
• Correll CU, Lencz T, Malhotra AK. Antipsychotic drugs and obesity. Trends Mol Med 2011;17:97-107
   PubMed Web of Science ®Google Scholar
• Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005;20:368-78
   PubMedGoogle Scholar
• Kim SF, Huang AS, Snowman AM, From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA 2007;104:3456-9
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Mancini DA, Basile VS. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 2001;62(Suppl 23):23-9
   PubMedGoogle Scholar
• Sussman N. The implications of weight changes with antipsychotic treatment. J Clin Psychopharmacol 2003;23:S21-6
   PubMed Web of Science ®Google Scholar
• Centorrino F, Cincotta SL, Talamo A, Hospital use of antipsychotic drugs: polytherapy. Compr Psychiatry 2008;49:65-9
   PubMed Web of Science ®Google Scholar
• Jerrell JM, McIntyre RS. Adverse events in children and adolescents treated with antipsychotic medications. Hum Psychopharmacol 2008;23:283-90
   PubMed Web of Science ®Google Scholar
• Reinstein MJ, Sirotovskaya LA, Jones LE, Effect of clozapine-quetiapine combination therapy on weight and glycaemic control: preliminary findings. Clin Drug Investig 1999;18:99-104
   Web of Science ®Google Scholar
• Karunakaran K, Tungaraza TE, Harborne GC. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia? J Psychopharmacol 2007;21:453-6
   PubMed Web of Science ®Google Scholar
• Ziegenbein M, Kropp S, Kuenzel HE. Combination of clozapine and ziprasidone in treatment-resistant schizophrenia: an open clinical study. Clin Neuropharmacol 2005;28:220-4
   PubMed Web of Science ®Google Scholar
• Henderson DC, Kunkel L, Nguyen DD, An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia. Acta Psychiatr Scand 2006;113:142-7
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Heikkinen ME, Olie JP, Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010;13:1115-25
   PubMed Web of Science ®Google Scholar
• Henderson DC, Fan X, Copeland PM, Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 2009;29:165-9
   PubMed Web of Science ®Google Scholar
• Henderson DC, Fan X, Copeland PM, Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia. Hum Psychopharmacol 2009;24:225-32
   PubMed Web of Science ®Google Scholar
• Chang JS, Ahn YM, Park HJ, Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008;69:720-31
   PubMed Web of Science ®Google Scholar
• Honer WG, Thornton AE, Chen EY, Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-82
   PubMed Web of Science ®Google Scholar
• Correll CU, Manu P, Olshanskiy V, Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 2009;302:1765-73
   PubMed Web of Science ®Google Scholar
• De Hert M, Correll CU, Bobes J, Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011;10:52
   PubMed Web of Science ®Google Scholar
• Kessing LV, Thomsen AF, Mogensen UB, Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010;197:266-71
   PubMed Web of Science ®Google Scholar
• Correll CU, Frederickson AM, Kane JM, Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007;89:91-100
   PubMed Web of Science ®Google Scholar
• Misawa F, Shimizu K, Fujii Y, Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study. BMC Psychiatry 2011;11:118
   PubMed Web of Science ®Google Scholar
• Krane-Gartiser K, Breum L, Glumrr C, Prevalence of the metabolic syndrome in Danish psychiatric outpatients treated with antipsychotics. Nord J Psychiatry 2011;65:345-52
   PubMed Web of Science ®Google Scholar
• Tirupati S, Chua LE. Obesity and metabolic syndrome in a psychiatric rehabilitation service. Aust NZ J Psychiatry 2007;41:606-10
   PubMed Web of Science ®Google Scholar
• Citrome L, Jaffe A, Levine J, Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv 2004;55:1006-13
   PubMed Web of Science ®Google Scholar
• Taylor D, Young C, Esop R, Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 2004;185:152-6
   PubMed Web of Science ®Google Scholar
• Buckley NA, Sanders P. Cardiovascular adverse effects of antipsychotic drugs. Drug Saf 2000;23:215-28
   PubMed Web of Science ®Google Scholar
• Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf 2010;5:97-104
   PubMedGoogle Scholar
• Ray WA, Chung CP, Murray KT, Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35
   PubMed Web of Science ®Google Scholar
• Ramos-Rios R, Arrojo-Romero M, Paz-Silva E, QTc interval in a sample of long-term schizophrenia inpatients. Schizophr Res 2010;116:35-43
   PubMed Web of Science ®Google Scholar
• Correll CU, Frederickson AM, Figen V, The QTc interval and its dispersion in patients receiving two atypical antipsychotics. Eur Arch Psychiatry Clin Neurosci 2009;259:23-7
   PubMed Web of Science ®Google Scholar
• Mackin P, Young AH. QTc interval measurement and metabolic parameters in psychiatric patients taking typical or atypical antipsychotic drugs: a preliminary study. J Clin Psychiatry 2005;66:1386-91
   PubMed Web of Science ®Google Scholar
• Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998;173:325-9
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Lonnqvist J, Wahlbeck K, 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374:620-7
   PubMed Web of Science ®Google Scholar
• Centorrino F, Goren JL, Hennen J, Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am J Psychiatry 2004;161:700-6
   PubMed Web of Science ®Google Scholar
• Barbui C, Nose M, Mazzi MA, Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol 2006;21:355-62
   PubMed Web of Science ®Google Scholar
• Ganesan S, Taylor R, Rabheru K, Antipsychotic polypharmacy does not increase the risk for side effects. Schizophr Res 2008;98:323-4
   PubMed Web of Science ®Google Scholar
• Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004;6:3-7
   PubMedGoogle Scholar
• Ziegenbein M, Sieberer M, Calliess IT, Combination of clozapine and aripiprazole: a promising approach in treatment-resistant schizophrenia. Aust NZ J Psychiatry 2005;39:840-1
   PubMed Web of Science ®Google Scholar
• Rocha FL, Hara C. Benefits of combining aripiprazole to clozapine: three case reports. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1167-9
   PubMed Web of Science ®Google Scholar
• Nielsen J, Meyer JM. Risk Factors for Ileus in Patients with Schizophrenia. Schizophr Bull 2010 Nov 26. [Epub ahead of print] PubMed PMID: 21112965
   Google Scholar
• Vinogradov S, Fisher M, Warm H, The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry 2009;166:1055-62
   PubMed Web of Science ®Google Scholar
• Sweeney JA, Keilp JG, Haas GL, Relationships between medication treatments and neuropsychological test performance in schizophrenia. Psychiatry Res 1991;37:297-308
   PubMed Web of Science ®Google Scholar
• Elie D, Poirier M, Chianetta J, Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder. J Psychopharmacol. 2010 Jul;24(7):1037-44. Epub 2009 Jan 22, PubMed PMID: 19164494
   PubMed Web of Science ®Google Scholar
• Hori H, Noguchi H, Hashimoto R, Antipsychotic medication and cognitive function in schizophrenia. Schizophr Res 2006;86:138-46
   PubMed Web of Science ®Google Scholar
• Kontis D, Theochari E, Kleisas S, Doubtful association of antipsychotic polypharmacy and high dosage with cognition in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010;34:1333-41
   PubMed Web of Science ®Google Scholar
• Davydov L, Botts SR. Clozapine-induced hypersalivation. Ann Pharmacother 2000;34:662-5
   PubMed Web of Science ®Google Scholar
• Naber D, Holzbach R, Perro C, Clinical management of clozapine patients in relation to efficacy and side-effects. Br J Psychiatry Suppl 1992; May;(17):54-9. PubMed PMID: 1358128
   PubMedGoogle Scholar
• Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol 2006;21:99-103
   PubMed Web of Science ®Google Scholar
• Husain Z, Almeciga I, Delgado JC, Increased FasL expression correlates with apoptotic changes in granulocytes cultured with oxidized clozapine. Toxicol Appl Pharmacol 2006;214:326-34
   PubMed Web of Science ®Google Scholar
• Lander M, Bastiampillai T. Neutropenia associated with quetiapine, olanzapine, and aripiprazole. Aust NZ J Psychiatry 2011;45:89
   PubMed Web of Science ®Google Scholar
• Ebert MH, Shader RI. Hepatic effects. In: Shader RI, DiMasccio A, editors. Psychotropic Drug Side Effects. Williams and Wilkins Co.; Baltimore: 1970. p. 175-97
   Google Scholar
• Atasoy N, Erdogan A, Yalug I, A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1255-60
   PubMed Web of Science ®Google Scholar
• Hummer M, Kurz M, Kurzthaler I, Hepatotoxicity of clozapine. J Clin Psychopharmacol 1997;17:314-17
   PubMed Web of Science ®Google Scholar
• Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 2000;22:73-81
   PubMed Web of Science ®Google Scholar
• Suzuki T, Uchida H, Watanabe K, A clinical case series of switching from antipsychotic polypharmacy to monotherapy with a second-generation agent on patients with chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:361-9
   PubMed Web of Science ®Google Scholar
• Essock SM, Schooler NR, Stroup TS, Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 2011;168:702-8
   PubMed Web of Science ®Google Scholar
• Kuwilsky A, Krumm B, Englisch S, Long-term efficacy and tolerability of clozapine combined with ziprasidone or risperidone. Pharmacopsychiatry 2010;43:216-20
   PubMed Web of Science ®Google Scholar
• Goren JL, Parks JJ, Ghinassi FA, When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf 2008;34:571-82
   PubMedGoogle Scholar
• Lieberman JA, Stroup TS, McEvoy JP, Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23
   PubMed Web of Science ®Google Scholar